Document:

<PAGE>

                                   EXHIBIT (j)
                           MARC PHARMACEUTICALS, INC.

                                                  January 1, 2004

Mr. Joel San Antonio
1204 Clubhouse Court
Southlake, Texas 76092

Dear Mr. San Antonio:

Marc Pharmaceuticals, Inc ("Marc") recognizes that being a Founder, your
business expertise and experience make you uniquely qualified to assist senior
management in identifying opportunities, developing strategies that will enhance
the company's product flow and efficiencies, increase market opportunities and
enhance the company's value. Therefore, Marc desires to enter into a five-year
relationship with you as an advisor to Marc's senior management effective as of
January 1, 2004.

In your capacity as an advisor, you will be given access to such proprietary
compounds and products, clinical records, confidential material, financial
statements, and other company information as you shall require. You understand
that this information is proprietary to Marc and you agree that you will take
reasonable precautions to preserve the confidentiality thereof. Marc understands
and acknowledges that your various other obligations and commitments make it
impossible for you to dedicate any specific, regular periods of time to this
undertaking. You agree, however, that you will use reasonable efforts to make
yourself available for meetings, either on-site or telephonic, and for
consultation with Marc's president and/or such other senior managers as the
president may request on an "as needed" basis.

In consideration for your services, you will receive an annual fee of One
Hundred Twenty Thousand Dollars ($120,000) payable in equal monthly
installments. In addition, Marc will pay to you an Automobile allowance of $1000
per month for the term of this agreement. Also you will be reimbursed for all
reasonable and customary expenses incurred in carrying out your duties
hereunder. In the event you desire to terminate this relationship, you may do so
by giving Marc's President and Chief Executive Officer written notice not less
than thirty (30) days prior to the effective date of such termination.

If the forgoing is acceptable to you, please sign and return the enclosed copy
of this letter. I am excited about your willingness to help us grow our company
and look forward to a long and successful relationship.

                                         Marc Pharmaceuticals, Inc.

                                         By:
                                            ----------------------------------
                                         President and Chief Executive Officer

                                       1
<PAGE>

Agreed and accepted this 1st day of January 2004.

------------------------------------
Joel San Antonio

                                       2<PAGE>

                                  EXHIBIT 10(l)

         THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT
         OF 1933, AS AMENDED. THE NOTE HAS BEEN ACQUIRED FOR INVESTMENT AND MUST
         BE HELD INDEFINITELY UNLESS IT IS SUBSEQUENTLY REGISTERED UNDER SAID
         ACT OR, IN THE OPINION OF COUNSEL TO THE COMPANY, AN EXEMPTION FROM
         REGISTRATION UNDER SAID ACT IS AVAILABLE.

                                 PROMISSORY NOTE

$___________________                                          _________, 2004

FOR VALUE RECEIVED, Marc Pharmaceuticals, Inc., having an address at 350 Bedford
Street, Stamford, CT 06901 ("Maker"), promises to pay to
__________________________________________________________________ ("Payee"), in
lawful money of the United States of America, the principal sum of
__________________________ ($_________), together with interest thereon accruing
at an annual rate equal to 20%, in the manner provided below ("Note"). Interest
shall be calculated on the basis of a year of 365 or 366 days, as applicable,
and charged for the actual number of days elapsed.

1. PAYMENTS

1.1 PRINCIPAL AND INTEREST

 All principal and accrued interest shall be paid in full on ___________, 2005
("Maturity Date").

1.2 MANNER OF PAYMENT

All payments of principal and interest on this Note shall be made by check at
__________________________________________________________________ or at such
other place in the United States of America as Payee shall designate to Maker in
writing.

1.3 PREPAYMENT

Maker may, without premium or penalty, at any time and from time to time, after
6 months from the date of the Note, prepay all or any portion of the outstanding
principal balance due under this Note, provided that each such prepayment is
accompanied by accrued interest on the amount of principal prepaid calculated to
the date of such prepayment. Any partial prepayments shall be applied first to
accrued interest and then to principal.

                                       1
<PAGE>

2. DEFAULTS

2.1 EVENTS OF DEFAULT

The occurrence of any one or more of the following events with respect to Maker
shall constitute an event of default hereunder ("Event of Default"):

(a) If Maker shall fail to pay when due any payment of principal or interest on
this Note.

(b) If, pursuant to or within the meaning of the United States Bankruptcy Code
or any other federal or state law relating to insolvency or relief of debtors (a
"Bankruptcy Law"), Maker shall (i) commence a voluntary case or proceeding; (ii)
consent to the entry of an order for relief against it in an involuntary case;
(iii) consent to the appointment of a trustee, receiver, assignee, liquidator or
similar official; (iv) make an assignment for the benefit of his creditors; or
(v) admit in writing its inability to pay its debts as they become due.

(c) If a court of competent jurisdiction enters an order or decree under any
Bankruptcy Law that (i) is for relief against Maker in an involuntary case, (ii)
appoints a trustee, receiver, assignee, liquidator or similar official for the
Maker or substantially all of the Maker's properties, or (iii) orders the
liquidation of the Maker, and in each case the order or decree is not dismissed
within 90 days.

2.2 REMEDIES

Upon the occurrence of an Event of Default hereunder (unless all Events of
Default have been cured or waived by Payee), (a) the interest rate will increase
to a default rate of the highest legal rate effective upon such Event of
Default, and (b) Payee may, at its option, (i) by written notice to Maker,
declare the entire unpaid principal balance of this Note, together with all
accrued interest thereon, immediately due and payable, and (ii) exercise any and
all rights and remedies available to it under applicable law, including, without
limitation, the right to collect from Maker all sums due under this Note. Maker
shall pay all reasonable costs and expenses incurred by or on behalf of Payee in
connection with Payee's exercise of any or all of its rights and remedies under
this Note, including, without limitation, reasonable attorneys' fees and
expenses.

3. REPRESENTATIONS BY PAYEE

Payee represents and warrants to Maker as follows:

         (a) Payee has received and examined all information concerning Maker
which Payee considers necessary to making an informed decision regarding this
Note. In addition, Payee has had the opportunity to ask questions of, and
receive answers from, the officers and agents of Maker concerning Maker and to
obtain such information, to the extent such persons possessed the same or could
acquire it without unreasonable effort or expense, as Payee deemed necessary to
verify the accuracy of the information referred to herein.

                                       2
<PAGE>

         (b) The Payee acknowledges and understands that: (i) the Maker will use
the proceeds of this Note for the Maker's outstanding debt, working capital and
executive compensation, (ii) the proceeds of the Note will not be sufficient to
provide the Maker with the necessary funds to achieve its current business plan,
(iii) the Maker does not have sufficient cash available to repay the Note, (iv)
this Note will not be guaranteed nor will it be secured by any assets of Maker
nor senior to any other indebtedness of Maker, and (v) the Payee bears the
economic risk of never being repaid on this Note.

         (c) The Payee hereby certifies that Payee is an "Accredited Investor"
(as that term is defined by Regulation D under the Securities Act of 1933, as
amended) because at least one of the following statements is applicable to
Payee:

               i.   The Payee is an "Accredited Investor" because the Payee had
                    individual income of more than $200,000 in each of the two
                    prior calendar years and reasonably expects to have
                    individual income in excess of $200,000 during the current
                    calendar year.

               ii.  The Payee is an "Accredited Investor" because the Payee and
                    his spouse together had income of more than $300,000 in each
                    of the two prior calendar years and reasonably expect to
                    have joint income in excess of $300,000 during the current
                    calendar year.

               iii. The Payee is an "Accredited Investor" because he has an
                    individual net worth, or he and his spouse have a joint net
                    worth of more than $1,000,000.

          (d)  Payee is acquiring this Note for his own account, for investment
               purposes only, and not with a view to the resale or distribution
               of all or any part thereof.

          (e)  Payee acknowledges that this Note (i) has not been registered
               under applicable securities laws, (ii) will be a "restricted
               security" as defined in applicable securities laws, (iii) has
               been issued in reliance on the statutory exemptions from
               registration contemplated by applicable securities laws based (in
               part) on the accuracy of Payee's representations contained
               herein, and (iv) will not be transferable without registration
               under applicable securities laws, unless an exemption from such
               registration requirements is available.

4. MISCELLANEOUS

4.1 WAIVER

The rights and remedies of Payee under this Note shall be cumulative and not
alternative. No waiver by Payee of any right or remedy under this Note shall be
effective unless in writing signed by Payee. Neither the failure nor any delay
in exercising any right, power or privilege under this Note will operate as a
waiver of such right, power or privilege and no single or partial exercise of
any such right, power or privilege by Payee will preclude any other or further
exercise of such right, power or privilege or the exercise of any other right,
power or privilege. To the maximum extent permitted by applicable law, (a) no
claim or right of Payee arising out of this Note can be

                                       3
<PAGE>

discharged by Payee, in whole or in part, by a waiver or renunciation of the
claim or right unless in a writing, signed by Payee; (b) no waiver that may be
given by Payee will be applicable except in the specific instance for which it
is given; and (c) no notice to or demand on Maker will be deemed to be a waiver
of any obligation of Maker or of the right of Payee to take further action
without notice or demand as provided in this Note.

Maker acknowledges that this Note and Maker's obligations under this Note are,
and shall at all times continue to be, absolute and unconditional in all
respects, and shall at all times be valid and enforceable. To the extent
permitted by applicable law, Maker hereby absolutely, unconditionally and
irrevocably forever waives any and all right to assert any defense, set-off,
offset, counterclaim, cross-claim or claim of any nature whatsoever with respect
to this Note or Maker's obligations hereunder.

4.2 NOTICES

Any notice or communication to be given hereunder by any party, to the other
party shall be in writing and shall be deemed to have been given when personally
delivered, or one day after the date sent by recognized overnight courier or
transmitted by facsimile, which transmission by facsimile has been confirmed or
three (3) days after the date sent by registered or certified mail, postage
prepaid, as follows:

                           if to Maker, addressed to it at:

                           Marc Pharmaceuticals, Inc.
                           350 Bedford Street
                            Stamford, CT 06901
                           Attn.:  Robert M. Cohen, President

                           with a copy to:

                           Tannenbaum Helpern Syracuse & Hirschtritt LLP
                           900 Third Avenue
                           New York, New York 10022
                           Attn:  Ralph Siciliano, Esq.

                           if to Payee, addressed to:

                           Name:
                                -----------------------------
                           Address:
                                   --------------------------

                           ----------------------------------

Or persons or addresses as may be designated in writing by the party to receive
such notice.

                                       4
<PAGE>

4.3 SEVERABILITY

If any provision in this Note is held invalid or unenforceable by any court of
competent jurisdiction, the other provisions of this Note will remain in full
force and effect. Any provision of this Note held invalid or unenforceable only
in part or degree will remain in full force and effect to the extent not held
invalid or unenforceable.

4.4 GOVERNING LAW

This Note will be governed by the laws of the State of New York without regard
to conflicts of laws principles.

4.5 ASSIGNMENT; PARTIES IN INTEREST

This Note shall bind Maker and its successors and assigns. This Note shall not
be assigned or transferred by Maker, without the express prior written consent
of Payee, and this Note will inure to the benefit of Payee and his heirs,
estates, representatives, administrators, successors and assigns.

4.6 SECTION HEADINGS, CONSTRUCTION

The headings of Sections in this Note are provided for convenience only and will
not affect its construction or interpretation. All references to "Section" or
"Sections" refer to the corresponding Section or Sections of this Note unless
otherwise specified.

All words used in this Note will be construed to be of such gender or number as
the circumstances require. Unless otherwise expressly provided, the words
"hereof" and "hereunder" and similar references refer to this Note in its
entirety and not to any specific section or subsection hereof.

4.7 SAVINGS CLAUSE

If, at any time, the rate of interest under this Note shall be deemed by any
competent court of law, governmental agency or tribunal to exceed the maximum
rate of interest permitted by the laws of any applicable jurisdiction or the
rules or regulations of any appropriate regulatory authority or agency, then
during such time as such rate of interest would be deemed excessive, that
portion of each interest payment attributable to that portion of such interest
rate that exceeds the maximum rate of interest so permitted shall be deemed a
voluntary prepayment of principal or, if all principal has been paid, that
portion of each interest payment attributable to that portion of such interest
rate that exceeds the maximum rate of interest so permitted shall be promptly
refunded to Maker.

                                       5
<PAGE>

4.8 WAIVER OF JURY TRIAL

MAKER AND PAYEE EACH HEREBY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION
DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS NOTE,
IT BEING AGREED THAT ALL SUCH TRIALS SHALL BE CONDUCTED SOLELY BY A JUDGE. MAKER
AND PAYEE EACH CERTIFY THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF EITHER HAS
REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE OTHER WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVERS. MAKER AND PAYEE EACH AGREE
AND ACKNOWLEDGE THAT IT HAS BEEN REPRESENTED BY INDEPENDENT COUNSEL IN
CONNECTION WITH THIS NOTE OR BEEN ADVISED THAT IT SHOULD BE REPRESENTED BY
INDEPENDENT COUNSEL IN CONNECTION WITH THIS NOTE. IF MAKER OR PAYEE HAS DECIDED
NOT TO BE REPRESENTED BY INDEPENDENT COUNSEL IN CONNECTION WITH THIS NOTE, IT
IRREVOCABLY AND FOREVER WAIVES ANY AND ALL DEFENSES OR RIGHTS ARISING OUT OF OR
RELATED TO SAID DECISION.

IN WITNESS WHEREOF, Maker has executed and delivered this Note as of the date
first stated above.

                                    MARC PHARMACEUTICALS, INC.

                                    By:
                                       ----------------------------
                                    Name:  Robert M. Cohen
                                    Title:  President

Accepted and Agreed to:

---------------------------
Payee

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]